07:51 AM EDT, 04/22/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Monday it has signed a capacity reservation and supply agreement with integrated development and manufacturing organization Cellares to manufacture CAR T cell therapies.

The pharmaceutical company said the deal is worth up to $380 million in upfront and milestone payments.

Under the agreement, Cellares will target certain Bristol-Myers Squibb CAR T cell therapies for its manufacturing platform Cell Shuttle and dedicate multiple Cell Shuttle and Cell Q systems with quality control for Bristol-Myers' exclusive use.